- Impression Healthcare (IHL) has filed a patent application covering IHL-42X in pill form for the treatment of Obstructive Sleep Apnoea (OSA)
- OSA is currently the second most diagnosed respiratory condition after asthma
- The existing treatment has found a high level of non-compliance due to it being intrusive and uncomfortable for patients and their partners
- Having this patent in place allows Impression to push ahead with further development of IHL-42X and target a market in need
- Impression shares remain flat and are trading for 6.5 cents each
Impression Healthcare (IHL) has filed a patent application covering IHL-42X in pill form to be used in the treatment of Obstructive Sleep Apnoea (OSA).
Impression is a leading developer of medical cannabis products and undertakes trials investigating the treatment of Obstructive Sleep Apnoea, Traumatic Brain Injury or Concussions, Gum Disease and Temporomandibular Joint Disorder.
The patent filing follows extensive work by Chief Medical Officer Dr Sud Agarwal and Dr David Cunnington, who is a globally-recognised sleep physician and member of the company’s medical advisory board.
“Having the patent in place affords the Impression team the relevant protection it needs in the near term to push ahead with further development of IHL-42X,” Chief Medical Officer and Non-executive Director Dr Sud Agarwal said.
Impression filed for registration for IHL-42X in August to conduct a six-week Phase 2a trial to test its effects in 30 patients.
OSA is currently the second most diagnosed respiratory condition after asthma.
Unfortunately, its under-treated because a high number of patients find the traditional continuous positive airway pressure (CPAP) device to be too intrusive and uncomfortable.
Having this patent application in place allows the company to commence further work related to initial in-human observations, in-vivo studies, dosage studies formulation refinement and other clinical activities.
Impression shares remain flat and are trading for 6.5 cents each at midday trade.